TLDR
HIMS stock drops 0.91% to $30.64 despite Hers launching across Australia nationwide.
Hers expands into Australia with new treatments for weight loss and women’s health.
Hims & Hers completes its Australian expansion following the Eucalyptus acquisition.
Hers introduces round-the-clock care and personalized treatments for women nationwide.
Australia’s growing telehealth market offers Hims & Hers new expansion opportunities.
Hims & Hers Health (HIMS) stock declined 0.91% to $30.64 on Monday, despite the company’s expansion into Australia’s women’s healthcare market. Shares lost $0.28 during regular trading before slipping another 0.13% to $30.60 in after-hours trading. Meanwhile, the company launched its Hers platform nationwide, expanding access to personalized healthcare services for Australian women.
Hims & Hers Health, Inc., HIMS
Hims & Hers Health Expands Women’s Healthcare Services Across Australia
Hims & Hers announced the official launch of Hers in Australia on October 12, expanding its international healthcare operations. The platform offers treatments covering weight management, hair regrowth, menopause, and perimenopause through digital consultations. Women can access healthcare professionals, medication support, and a dedicated care team available around the clock.
The expansion follows the company’s acquisition of Eucalyptus earlier this year, strengthening its position in Australia’s digital healthcare sector. Under the transition, Eucalyptus’ existing women’s healthcare platform, Juniper, will operate under the Hers brand. Meanwhile, the earlier rebranding of Pilot to Hims in August completed the company’s broader Australian platform rollout.
The company introduced specialized weight management programs that combine medical treatment with nutritional guidance and fitness support. Furthermore, Hers provides hair regrowth treatments and services addressing hormonal health concerns throughout different life stages. The platform also allows patients to request female practitioners and access a community exceeding 27,000 women.
Hers Targets Healthcare Access Gaps With Digital Treatment Programs
Hers plans to address healthcare access challenges affecting women across Australia’s metropolitan and regional communities. According to company research, 52% of surveyed Australian women reported experiencing weight-related judgment from healthcare professionals. Among those respondents, 72% subsequently avoided seeking clinical assistance, highlighting barriers to routine treatment.
The company also identified healthcare costs and geographic limitations as obstacles to accessing specialized medical services. Nearly 30% of Australians live in regional and rural communities, where specialist appointments can require extended waiting periods. Hers aims to connect patients with medical professionals through remote consultations and continuous digital support.
Rebecca Holdt, the company’s international product vice president, emphasized digital healthcare’s role in improving nationwide access to treatment. Meanwhile, Australian Chief Medical Officer Matt Vickers highlighted the need for evidence-based services addressing women’s broader healthcare requirements. Existing Juniper patients will retain their Australian practitioners while gaining access to additional treatment options.
Australia Expansion Strengthens Hims & Hers International Operations
The Australian launch extends Hims & Hers’ existing international presence across North America and Europe. Furthermore, the company enters a growing telehealth market with increasing demand for accessible digital healthcare services. Industry projections cited by the company estimate Australia’s telehealth market could reach $2.56 billion by 2034.
Gus Wood will oversee Australian operations as general manager, supported by Chief Medical Officer Matt Vickers. Hers Chief Medical Officer Jessica Shepherd will provide clinical oversight to maintain the company’s international healthcare standards. The leadership structure combines local medical expertise with the company’s wider technology and treatment infrastructure.
Despite the expansion, Hims & Hers Health stock ended Monday’s session lower, extending its losses into after-hours trading. The company’s latest rollout broadens its healthcare offerings beyond existing services and establishes a unified brand across Australia. However, Monday’s stock decline contrasted with the company’s continued expansion into international digital healthcare markets.
The post Hims & Hers Health (HIMS) Stock: Slides Despite Major Australia Expansion appeared first on Blockonomi .
